GlassScriptPhysician profile
Anju Johnson
NPI 1104392513
$3,178.38
in general payments reported to CMS, 2019-2025
25 companies · $33.86 in 2025
The $33.86 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,719 · 2022: $1,380 · 2023: $45.06 · 2025: $33.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $632.68 | 2021-2022 | |
| Astellas Pharma US INC | $516.58 | 2021-2022 | |
| Abbvie INC. | $294.68 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $251.84 | 2021-2022 | |
| Urogen Pharma, INC. | $162.40 | 2021 | |
| Urovant Sciences INC | $141.35 | 2021-2022 | |
| Antares Pharma, INC. | $126.91 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $119.97 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $112.66 | 2021-2022 | |
| Pfizer INC. | $106.80 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $106.47 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $99.66 | 2021-2022 | |
| Axonics, INC. | $75.49 | 2022 | |
| Blue Earth Diagnostics | $69.14 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $66.48 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $50.03 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $44.90 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $36.51 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $33.95 | 2022 | |
| Clarus Therapeutics INC. | $28.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.82 | 2022 | |
| Clovis Oncology, INC. | $20.66 | 2021 | |
| Allergan, INC. | $19.90 | 2021 | |
| Palette Life Sciences, INC. | $19.26 | 2022 | |
| Amgen INC. | $17.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anju Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.